Over 10,000 results
Page 2 of 100
424B5
g0csabj
11 Jun 24
Prospectus supplement for primary offering
4:49pm
10-K/A
xbcjvr
11 Jun 24
Annual report (amended)
4:23pm
6-K
EX-99.1
damh2zpi9ze6swax
11 Jun 24
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
1:54pm
6-K
EX-99.4
mlpbptt
11 Jun 24
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
1:54pm
6-K
EX-99.2
uoj4r
11 Jun 24
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
1:54pm
6-K
EX-99.4
6hof2kir
11 Jun 24
Pharvaris Announces Annual Meeting of Shareholders
6:52am
8-K
EX-99.01
zk8ic9lc
10 Jun 24
Regulation FD Disclosure
8:53am
F-1
6ufqe48o4akr9j3 mx
7 Jun 24
Registration statement (foreign)
2:04pm
424B3
w0fl0n pi
6 Jun 24
Prospectus supplement
4:34pm
8-K
EX-99.2
x83v8m9zmntkrcy3zo33
6 Jun 24
Regulation FD Disclosure
4:02pm
POS AM
sq1113
6 Jun 24
Prospectus update (post-effective amendment)
3:19pm
253G2
fslr mh3zcdm2djztvpw
6 Jun 24
Offering circular supplement
12:39pm
8-K
EX-99.1
z726 sgg221lvanpal
6 Jun 24
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
11:16am